

ASX Release

SUDA LTD APPOINTS NEW CHAIRMAN

PERTH, AUSTRALIA - 19 December 2013: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that Mr. Stephen Carter has decided that the timing is right for him to step down as Chairman of the Board and to focus on leading the executive team in his role as Chief Executive Officer. The Board of Directors has appointed Non-Executive Director, Mr. Michael Stewart, to the position of Non-Executive Chairman. These changes will take effect from 1 January 2014 and align the Company with the ASX's principles of good corporate governance and best practice recommendations.

Mr. Stewart joined the Board in June 2009. He has extensive experience with small and mid-cap companies with a background in corporate finance and management. He has also been involved in bilateral donor funded and World Bank co-financed aid projects in under-developed countries, which is particularly relevant to SUDA's anti-malarial treatment, ArTiMist™. Mr. Carter joined SUDA as Director and CEO in October 2009 and took on the added responsibility of Executive Chairman in December 2012.

Michael Stewart commented on the Board changes: "The recent strong endorsement from institutional investors and consolidation of the NovaDel and ArTiMist™ assets has been a major step forward for the company. As CEO, Stephen has a very clear plan to reposition SUDA Ltd and how best to realize the value of our pipeline of oro-mucosal therapeutic sprays. I am proud to take on the role of Chairman and look forward to working with Stephen, the Board and the management team as we deliver greater value to our shareholders and other stakeholders."

Stephen Carter said: "I have been discussing the split of Chairman and CEO with the Board for some time and feel the timing is right to realign SUDA with corporate governance best practices. Separating the positions of Chairman and CEO provides clearer reporting lines and allows me to focus on executing the Company's strategic plan and managing the Company's operations and performance. Michael is highly experienced in managing Boards and I have valued his judgement and insight over the past three years since I joined SUDA."



Further information:
STEPHEN CARTER
EXECUTIVE CHAIRMAN
SUDA LTD
Tel: +61 8 6142 5555
sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using novel formulations of existing off-patent pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's most advanced product is a novel sub-lingual treatment, ArTiMist™, for severe malaria in children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other development stage products include orals sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting and erectile dysfunction.